Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial

BACKGROUND: The addition of trastuzumab (T) and lapatinib (L) to neoadjuvant chemotherapy increases the pathological complete response (pCR) rate in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. We investigated the efficacy of T or L with neoadjuvant che...

Descripción completa

Detalles Bibliográficos
Autores principales: Alba, E, Albanell, J, de la Haba, J, Barnadas, A, Calvo, L, Sánchez-Rovira, P, Ramos, M, Rojo, F, Burgués, O, Carrasco, E, Caballero, R, Porras, I, Tibau, A, Cámara, M C, Lluch, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3950860/
https://www.ncbi.nlm.nih.gov/pubmed/24457911
http://dx.doi.org/10.1038/bjc.2013.831

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3950860/
https://www.ncbi.nlm.nih.gov/pubmed/24457911
http://dx.doi.org/10.1038/bjc.2013.831

Ejemplares similares